Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
D-Tryptophan is a D-amino acid with diverse biological activities. It has been shown to promote skin wound healing, particularly in diabetic models, by modulating extracellular matrix remodeling through the upregulation of matrix metalloproteinases (MMP1, MMP3, MMP-9), influencing signaling pathways by upregulating Janus kinase 2 (JAK2) and mitogen-activated protein kinase (MAPK), reducing pro-inflammatory cytokines (tumor necrosis factor-α, interleukin-1β, interleukin-6), suppressing caspase-3, and enhancing angiogenesis via hypoxia-inducible factor-1α (HIF-1α) activation. Beyond wound healing, D-Tryptophan also exhibits antifungal activity against plant pathogenic fungi like Botrytis cinerea and Sclerotinia sclerotiorum, and can inhibit bacterial biofilm formation, specifically reducing avian pathogenic Escherichia coli biofilm. It is also recognized as a functional metabolite.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on D-Tryptophan.